Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Health Minister Opposed to ¥220 Bil. Cut in Social Security Spending
June 22, 2009
- NHI Price Listing Recommended for Approval for Nine APIs
June 22, 2009
- GENERICS NEWS IN BRIEF
June 22, 2009
- Generics May Be Approved Even if Original Drugs Are Covered by Valid Use Patents
June 22, 2009
- Pharmacies Should Give List of Generics They Stock to Medical Institutions: Mr Kinoshita
June 22, 2009
- Taiyo Aims at Sales of Over ¥50 Bil. with 227 MRs in FY2009
June 22, 2009
- R&D NEWS IN BRIEF
June 22, 2009
- Top-Four Generic Firms' Business Grows by Leaps and Bounds
June 22, 2009
- Gov't to Consider Patent Rights on Treatment Regimens
June 22, 2009
- BUSINESS NEWS IN BRIEF
June 22, 2009
- 52nd JDS Annual Meeting
June 22, 2009
- Ultmarc to Hire More Healthcare Professionals to Provide More Customer-Oriented Services
June 22, 2009
- Larger-Scale, Dose-Finding PII Studies Necessary for Anticoagulants: Dr C.M. Gibson
June 22, 2009
- Give Incentives to Those Who Settle Prices Earlier: Mr Bessho
June 22, 2009
- New Antithrombotic Drugs That Solve Dilemma of Thrombotic Events and Hemorrhagic Events Needed: Prof. Goto
June 22, 2009
- Mediceo Paltac to Invest in Drug Wholesaler in China
June 22, 2009
- Sales of Ethical Drugs Up 2.4% in FY2008 Compared to FY2007
June 22, 2009
- Production of Drugs May Be Negatively Affected by Healthcare Reform: YANO Research
June 22, 2009
- Tadalafil Improves PAH Patients' Exercise Capacity: Eli Lilly, United Therapeutics
June 22, 2009
- Wyeth to Improve RA Patients' Access to Biologics
June 22, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…